Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 13/20 | 0.43 |
| ▸ | MAOB | P27338 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30251337 | 1.00 | CYP19A1 (0.43) | CYP19A1MAOBCYP3A4GPR119 | |
| SCHEMBL32675590 | 1.00 | CYP19A1 (0.43) | CYP19A1MAOBCYP3A4GPR119 | |
| SCHEMBL23905963 | 1.00 | CYP19A1 (0.43) | CYP19A1MAOBCYP3A4GPR119 | |
| SCHEMBL23882769 | 1.00 | CYP19A1 (0.43) | CYP19A1MAOBCYP3A4GPR119 | |
| SCHEMBL23906288 | 0.82 | BRD4 (0.53) | CYP19A1MAOB | |
| SCHEMBL23905929 | 0.82 | MAOB (0.57) | MAOB | |
| SCHEMBL11377697 | 0.78 | CYP19A1 (0.63) | CYP19A1MAOBCYP3A4 | |
| SCHEMBL23906322 | 0.76 | MAOB (0.46) | CYP19A1MAOB | |
| SCHEMBL23882766 | 0.76 | MAOB (0.46) | CYP19A1MAOB | |
| SCHEMBL23906152 | 0.76 | MAOB (0.46) | CYP19A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| WO-2021198283-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | HLA-DRB1, CD74, HLA-C | CYP19A1 3518/4885MAOB 1451/4885CYP3A4 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.